Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis

Gastroenterology

Volumn 156, Issue 5, 2019, Pages 1440-1454.e2

  Paramsothy, Sudarshan ^a,b,c,e,f   Nielsen, Shaun ^a   Kamm, Michael A ^d   Deshpande, Nandan P ^a   Faith, Jeremiah J ^b   Clemente, Jose C ^b   Paramsothy, Ramesh ^g   Walsh, Alissa J ^c   van den Bogaerde, Johan ^e   Samuel, Douglas ^f   Leong, Rupert W L ^f   Connor, Susan ^g   Ng, Watson ^g   Lin, Enmoore ^h   Borody, Thomas J ^h   Wilkins, Marc R ^a   Colombel, Jean Frederic ^b   Mitchell, Hazel M ^a   Kaakoush, Nadeem O ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c ST VINCENT S HOSPITAL   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e NAMBOUR GENERAL HOSPITAL   (Australia)

^f BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^g LIVERPOOL HOSPITAL   (Australia)

^h Centre for Digestive Diseases   (Australia)

Author keywords

FOCUS Trial; Inflammatory Bowel Diseases; Metabolism; Microbiome

Indexed keywords

ENEMA; HEME; LIPOPOLYSACCHARIDE; RNA 16S; SHORT CHAIN FATTY ACID; BIOLOGICAL MARKER;

AMPLICON; ARTICLE; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTEROIDES; CARBOHYDRATE SYNTHESIS; COLON FLORA; COLONOSCOPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENRICHMENT CULTURE; ESCHERICHIA; EUBACTERIUM; EUBACTERIUM HALLII; FATTY ACID SYNTHESIS; FECAL MICROBIOTA TRANSPLANTATION; FUSOBACTERIUM; FUSOBACTERIUM GONIDIAFORMANS; HUMAN; INTESTINE BIOPSY; MAJOR CLINICAL STUDY; METABOLITE; METABOLOME; METAGENOMICS; MICROBIAL DIVERSITY; NONHUMAN; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RNA TRANSCRIPTION; ROSEBURIA; ROSEBURIA INULIVORANS; STREPTOCOCCUS; SUTTERELLA WADSWORTHENSIS; ULCERATIVE COLITIS; UNRELATED DONOR; BACTERIUM; CLASSIFICATION; FECES; GENETICS; GROWTH, DEVELOPMENT AND AGING; INTESTINE FLORA; METABOLISM; METABOLOMICS; MICROBIOLOGY; NEW SOUTH WALES; RIBOTYPING; TIME FACTOR; TREATMENT OUTCOME;

BACTERIA; BIOMARKERS; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; FECAL MICROBIOTA TRANSPLANTATION; FECES; GASTROINTESTINAL MICROBIOME; HUMANS; METABOLOMICS; NEW SOUTH WALES; REMISSION INDUCTION; RIBOTYPING; TIME FACTORS; TREATMENT OUTCOME;

EID: 85063110620     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2018.12.001     Document Type: Article

References (49)

1. Borody, T.J., Brandt, L.J., Paramsothy, S., Therapeutic fecal microbiota transplantation: current status and future developments. Curr Opin Gastroenterol 30 (2014), 97–105.
2. Kelly, C.R., Kahn, S., Kashyap, P., et al. Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology 149 (2015), 223–237.
3. Paramsothy, S., Rosenstein, A.K., Mehandru, S., et al. The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. Mucosal Immunol 11 (2018), 1558–1570.
4. Moayyedi, P., Surette, M.G., Kim, P.T., et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149 (2015), 102–109.
5. Paramsothy, S., Kamm, M.A., Kaakoush, N.O., et al. Multidonor intensive fecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 389 (2017), 1218–1228.
6. Costello, S., Waters, O., Bryant, R., et al. Short duration, low intensity pooled fecal microbiota transplantation induces remission in patients with mild-moderately active ulcerative colitis: a randomised controlled trial. Gastroenterology 152:5 Suppl 1 (2017), S198–S199.
7. Paramsothy, S., Paramsothy, R., Rubin, D.T., et al. Fecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 11 (2017), 1180–1199.
8. Costello, S.P., Soo, W., Bryant, R.V., et al. Systematic review with meta-analysis: fecal microbiota transplantation for the induction of remission for active ulcerative colitis. Aliment Pharmacol Therap 46 (2017), 213–224.
9. Allegretti, J., Eysenbach, L.M., El-Nachef, N., et al. The current landscape and lessons from fecal microbiota transplantation for inflammatory bowel disease: past, present, and future. Inflamm Bowel Dis 23 (2017), 1710–1717.
10. Rossen, N.G., Fuentes, S., van der Spek, M.J., et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 149 (2015), 110–118.
11. Fuentes, S., Rossen, N.G., van der Spek, M.J., et al. Microbial shifts and signatures of long-term remission in ulcerative colitis after fecal microbiota transplantation. ISME J 11 (2017), 1877–1889.
12. Ott, S.J., Waetzig, G.H., Rehman, A., et al. Efficacy of sterile fecal filtrate transfer for treating patients with Clostridium difficile infection. Gastroenterology 152 (2017), 799–811.
13. Schloss, P.D., Westcott, S.L., Ryabin, T., et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol 75 (2009), 7537–7541.
14. Kozich, J.J., Westcott, S.L., Baxter, N.T., et al. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. Appl Environ Microbiol 79 (2013), 5112–5120.
15. Quast, C., Pruesse, E., Yilmaz, P., et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res 41 (2013), D590–D596.
16. Edgar, R.C., Haas, B.J., Clemente, J.C., et al. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics 27 (2011), 2194–2200.
17. Wang, Q., Garrity, G.M., Tiedje, J.M., et al. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol 73 (2007), 5261–5267.
18. Westcott, S.L., Schloss, P.D., OptiClust, an improved method for assigning amplicon-based sequence data to operational taxonomic units. mSphere, 2, 2017 pii: e00073-17.
19. Schmieder, R., Edwards, R., Fast identification and removal of sequence contamination from genomic and metagenomic datasets. PLoS One, 6, 2011, e17288.
20. Cox, M.P., Peterson, D.A., Biggs, P.J., SolexaQA: at-a-glance quality assessment of Illumina second-generation sequencing data. BMC Bioinformatics, 11, 2010, 485.
21. Truong, D.T., Franzosa, E.A., Tickle, T.L., et al. MetaPhlAn2 for enhanced metagenomic taxonomic profiling. Nat Methods 12 (2015), 902–903.
22. Hall, A.B., Yassour, M., Sauk, J., et al. A novel Ruminococcus gnavus clade enriched in inflammatory bowel disease patients. Genome Med, 9, 2017, 103.
23. Oksanen J, Blanchet FG, Friendly M, et al. Vegan: community ecology package, 2017. Available at: https://cran.r-project.org/web/packages/vegan/vegan.pdf.
24. Love, M.I., Huber, W., Anders, S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol, 15, 2014, 550.
25. Segata, N., Izard, J., Waldron, L., et al. Metagenomic biomarker discovery and explanation. Genome Biol, 12, 2011, R60.
26. Engels, C., Ruscheweyh, H.J., Beerenwinkel, N., et al. The common gut microbe Eubacterium hallii also contributes to intestinal propionate formation. Front Microbiol, 7, 2016, 713.
27. Jain, V., Kumar, M., Chatterji, D., ppGpp: stringent response and survival. J Microbiol 44 (2006), 1–10.
28. Wehrli, W., Ansamycins. Chemistry, biosynthesis and biological activity. Top Curr Chem 72 (1977), 21–49.
29. Tiratterra, E., Franco, P., Porru, E., et al. Role of bile acids in inflammatory bowel disease. Ann Gastroenterol 31 (2018), 266–272.
30. Ohkusa, T., Okayasu, I., Ogihara, T., et al. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut 52 (2003), 79–83.
31. Strauss, J., Kaplan, G.G., Beck, P.L., et al. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis 17 (2011), 1971–1978.
32. Darfeuille-Michaud, A., Boudeau, J., Bulois, P., et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 127 (2004), 412–421.
33. Citron, D.M., Update on the taxonomy and clinical aspects of the genus Fusobacterium. Clin Infect Dis 35 (2002), S22–S27.
34. Kostic, A.D., Chun, E., Robertson, L., et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14 (2013), 207–215.
35. Mima, K., Sukawa, Y., Nishihara, R., et al. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol 1 (2015), 653–661.
36. Mima, K., Nishihara, R., Qian, Z.R., et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut 65 (2016), 1973–1980.
37. Bullman, S., Pedamallu, C.S., Sicinska, E., et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 358 (2017), 1443–1448.
38. Hussan, H., Clinton, S.K., Roberts, K., et al. Fusobacterium's link to colorectal neoplasia sequenced: a systematic review and future insights. World J Gastroenterol 23 (2017), 8626–8650.
39. Swidsinski, A., Dorffel, Y., Loening-Baucke, V., et al. Acute appendicitis is characterised by local invasion with Fusobacterium nucleatum/necrophorum. Gut 60 (2011), 34–40.
40. Roblin, X., Neut, C., Darfeuille-Michaud, A., et al. Local appendiceal dysbiosis: the missing link between the appendix and ulcerative colitis?. Gut 61 (2012), 635–636.
41. Ley, R.E., Gut microbiota in 2015: Prevotella in the gut: choose carefully. Nat Rev Gastroenterol Hepatol 13 (2016), 69–70.
42. Raetz, C.R., Whitfield, C., Lipopolysaccharide endotoxins. Annu Rev Biochem 71 (2002), 635–700.
43. Choby, J.E., Skaar, E.P., Heme synthesis and acquisition in bacterial pathogens. J Mol Biol 428 (2016), 3408–3428.
44. Ogata, H., Goto, S., Sato, K., et al. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 27 (1999), 29–34.
45. Atarashi, K., Suda, W., Luo, C., et al. Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation. Science 358 (2017), 359–365.
46. Staley, C., Kaiser, T., Vaughn, B.P., et al. Predicting recurrence of Clostridium difficile infection following encapsulated fecal microbiota transplantation. Microbiome, 6, 2018, 166.
47. Khanna, S., Vazquez-Baeza, Y., González, A., et al. Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease. Microbiome, 5, 2017, 55.
48. Smillie, C.S., Sauk, J., Gevers, D., et al. Strain tracking reveals the determinants of bacterial engraftment in the human gut following fecal microbiota transplantation. Cell Host Microbe 23 (2018), 229–240.
49. Seekatz, A.M., Theriot, C.M., Rao, K., et al. Restoration of short chain fatty acid and bile acid metabolism following fecal microbiota transplantation in patients with recurrent Clostridium difficile infection. Anaerobe 53 (2018), 64–73.